ClinicalTrials.gg
TerminatedNCT02679339Updated Feb 10, 2016

Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

A Phase 1 interventional study of CNTX-2022 (lidocaine gel, 40%) and Placebo in Acute-onset Herpes Zoster Pain, sponsored by Centrexion Therapeutics. Terminated at 1 site in Australia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-02-10.

Sponsored by Centrexion Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Limited patient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Herpes Zoster with a site in Australia — none open to participants now, 3 under way, 1 of them phase 3. Herpes Zoster · Australia.

Enrollment
16th of 16
1 · median 484
Started
2015
the only one that year
Phase 1
6 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
1 of 17
Centrexion Therapeutics

Among the 17 studies in Herpes Zoster with a site in Australia, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 1, and was the 8th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 17 studies in Herpes Zoster with a site in Australia is open now. The open studies under Herpes Zoster, anywhere →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Herpes Zoster with a site in Australia as a file.
02

Study summary

Study 2022-HZ-011 will utilize a randomized withdrawal (RW), double-blind, placebo controlled design in which the PK and safety of CNTX 2022 (40% anhydrous lidocaine gel) will be evaluated in subjects with acute-onset herpes zoster pain.

03

Conditions studied

  • Acute-onset Herpes Zoster Pain
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female ≥ 18 years of age and ≤ 85 years of age.
  2. Subject has brush-evoked allodynic pain intensity score ≥ 4 using the NPRS as determined by pain assessment during the physical examination at screening.

    a. Onset must have occurred ≤ 20 days prior to randomization

  3. Subject has an average daily pain intensity score of ≥ 4 using the NPRS as determined by pain assessment during the physical examination at screening.
  4. Subject must have a diagnosis of herpes zoster (shingles).
  5. Subject has rash limited to trunk and limbs, with a total surface area of up to 300 cm2.

Exclusion criteria

Exclusion Criteria:

  1. Subject has an active herpes zoster lesion on the face, head, neck, genital or rectal areas.
  2. Subject has rash limited to trunk and limbs, with a total surface area greater than 300 cm2.
  3. Subject has a known history of allergic reaction, , or intolerance to lidocaine, ingredients of the study drug, or local anesthetics of the amide type.
  4. Subject has target skin area (allodynic area and surrounding skin) that is not intact, is inflamed, or in the opinion of the Principal Investigator, consistent with rash due to acute herpes zoster.
  5. Subject has any other form of pain that was not discernible from herpes zoster (shingles) allodynia.
  6. Subject is taking Class I antiarrhythmic drugs (e.g., tocainide, mexiletine), or medications that could interact with the study drug or interfere with its evaluation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    CNTX-2022 (lidocaine gel, 40%)

    Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.

    Drug: CNTX-2022 (lidocaine gel, 40%)

  • Placebo comparator
    Placebo

    Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.

    Drug: Placebo

Interventions

  • DrugCNTX-2022 (lidocaine gel, 40%)
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. To evaluate the safety of topically applied 40% lidocaine gel measuring incidence, intensity, relationship, and seriousness of treatment-emergent AEs

    Time frame: 28 days

  2. To evaluate the pharmacokinetics of topically applied 40% lidocaine gel measuring Tmax

    Time frame: 28 days

Secondary outcomes

  1. To assess the effect of 40% lidocaine gel on 0-10 numeric pain rating scale (NPRS) scores related to acute herpes zoster

    Time frame: 28 days

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 10, 2016
Start
Jan 2015
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Feb 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02679339
Lead sponsor
Centrexion Therapeutics
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Jan 2015
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Feb 10, 2016

Study contacts

Michael Araco, MD
principal investigator · Nucleus Network Melbourne, Australia
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion